KPV vs Thymosin Alpha-1
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
KPV
KPV is a C-terminal tripeptide fragment (Lys-Pro-Val) of alpha-melanocyte stimulating hormone (α-MSH). Despite its small size — just three amino acids — it retains the anti-inflammatory core activity of its parent molecule without the melanogenic effects. It is one of the most researched peptides for gut inflammation, IBD, and intestinal permeability, with the ability to act locally in the gut when administered orally.
Full profileThymosin Alpha-1
Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide naturally derived from the thymus gland. It plays a central role in regulating immune function — specifically in the maturation and differentiation of T-cells. Unlike most research peptides, Thymosin Alpha-1 has approved clinical use in multiple countries (China, Italy, and others) for hepatitis B, hepatitis C, and as an immune adjuvant in cancer patients undergoing chemotherapy. In the US it is sold as Zadaxin and used as a research compound.
Full profile| KPV | Thymosin Alpha-1 | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | Lys-Pro-Val, Alpha-MSH C-terminal tripeptide | Tα1, Thymalfasin, Zadaxin |
| Evidence | Research-stage | Research-stage |
| Dosing range | 250mcg–1000mcg mcg, Once or twice daily | 900mcg–3.2mg mg, 2–3 times per week subcutaneously |
| Administration | Subcutaneous injection, Oral (encapsulated — for gut-specific delivery), Intranasal | Subcutaneous injection |
| Key side effects | Generally well-tolerated, Mild injection site irritation, Transient headache (uncommon), No melanogenic effects (does not cause tanning unlike full α-MSH) | Generally very well tolerated, Mild injection site reactions (most common), Transient fatigue in initial doses, Flu-like symptoms (rare) |
| Cited sources | 3 references | 4 references |
Key differences
- Administration: KPV — Subcutaneous injection, Oral (encapsulated — for gut-specific delivery), Intranasal; Thymosin Alpha-1 — Subcutaneous injection.
- Dosing units differ: KPV is dosed in mcg, Thymosin Alpha-1 in mg — they operate at different scales.
- Frequency: KPV is typically Once or twice daily; Thymosin Alpha-1 is 2–3 times per week subcutaneously.
- Research depth: this profile cites 3 sources for KPV vs 4 for Thymosin Alpha-1.
How each works
KPV
KPV exerts anti-inflammatory effects through melanocortin receptor-independent mechanisms as well as via MC1R and MC3R activation. It downregulates NF-κB, inhibits pro-inflammatory cytokines (TNF-α, IL-1β, IL-8), and reduces neutrophil infiltration in colonic tissue. Uniquely for a peptide, KPV is acid-stable enough to survive gastric transit and reach the intestinal mucosa intact, making oral delivery viable for gut-targeted applications — a significant advantage over most injectable-only peptides.
Thymosin Alpha-1
Extensive human clinical research documents Tα1's immune-modulating effects. It increases T-cell counts, enhances NK cell activity, and promotes Th1 cytokine balance. Multiple randomized trials have shown efficacy in treating chronic hepatitis B and C, reducing infection severity in critically ill patients, and improving outcomes in sepsis. More recent research investigates its role in long COVID immune dysregulation. It is considered one of the best-studied peptides in immunology.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.